5 Key Sessions, Interviews at ASCO Annual Meeting 2023

Pharmacy Times® will be covering the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting from June 2 to June 6. The ASCO conference brings influential cancer experts from across to the globe to Chicago every year to discuss the late-breaking-cancer research, groundbreaking therapies, and innovative technologies impacting the oncology field.

This year, the conference will have more than 200 sessions, which will provide oncology pharmacy professionals with opportunities for valuable updates in the field, as well as career development and education. ASCO also provides experts with the opportunity to engage with in-depth discussions and forge new connections with others in the field.

Stay tuned on PharmacyTimes.com for exclusive session coverage and interviews with session presenters, such as:

• An interview with Ramaswamy Govindan, MD, a medical oncologist at Washington University in St. Louis, Missouri, who will lead an in-person workshop that teaches oncologists how to do genomic testing in cancer. Govindan discusses the importance of these tests and its impact on choosing more suitable therapeutic options.
• Coverage of the session titled “Cancer During Pregnancy: Medical, Psychosocial, Ethical, and Legal Considerations,” which will cover frameworks for patient-centered care, treatment options and cancer management, and obstetric and neonatal issues in multidisciplinary management of cancer.
• A discussion with Bradley J. Monk, MD, who will discuss pembrolizumab (Keytruda; Merck & Co) and chemotherapy as a novel first-line treatment for persistent, recurrent, or metastatic cervical cancer. Monk will break down findings from the KEYNOTE-826 trial (NCT03635567) and describe the clinical applications of this research to improve patient outcomes.
• Coverage of a session focused on the review of FDA accelerated approvals in oncology. The session will go over the current approval process and FDA perspective, will analyse the merits of the patient perspective on treatment regulation, and will discuss updating the current pathways for treatment approvals.
• Coverage of a session that provides insight into chimeric antigen receptor T-related toxicities. Presentations in this session include “Perspective on Cytokine Release Syndrome in Patients With Solid Tumors Receiving T-Cell Therapies” led by John B. A. G. Haanen, MD, PhD, of the Netherlands Cancer Institute and “Perspective on Incidence and Management of Neurotoxicity” by Bianca Santomasso, MD, PhD, of Memorial Sloan Kettering Cancer Center.

Follow Pharmacy Times’ coverage of the conference on our website and on social media for all of the latest updates.